Glamour South Africa has published an interview with Dr Ashley Naidoo of BiomeRenew, in which the clinician sets out her position on the skin microbiome and what it means for everyday skincare choices.

The conversation centers on a premise that has moved from the research periphery into mainstream dermatologic discussion over the past decade: the skin is not a sterile surface but a resident ecosystem, and the composition of that ecosystem influences barrier function, inflammation and treatment response.

Dr Naidoo speaks to Glamour in her capacity at BiomeRenew, a company positioned in the growing microbiome-focused skincare category. That category has expanded rapidly as consumers and clinicians alike seek evidence-based alternatives to products that strip or disrupt the skin's resident flora.

Why the microbiome conversation matters now

For dermatologists, the microbiome is no longer an abstract research topic. Dysbiosis of the skin microbiome has been implicated in the pathophysiology of several conditions clinicians manage daily, including eczema, acne and rosacea. The scientific literature has linked reduced microbial diversity on the skin to atopic dermatitis flares, and specific organisms such as Cutibacterium acnes subtypes remain central to acne pathogenesis discussions.

Interviews like this one matter to the field because they signal how microbiome science is being translated for the public. When a clinician attached to a commercial skincare brand explains these concepts in consumer media, the framing can either reinforce or muddy the evidence picture dermatologists try to establish in consultation rooms.

What the interview covers

Glamour's discussion with Dr Naidoo addresses the relationship between microbial balance and better skincare outcomes. The piece forms part of the magazine's beauty and wellness coverage, where microbiome claims have become a regular feature of product marketing across the South African and global markets.

Readers of Derm Field will recognize the pattern: a clinician-led brand enters the consumer conversation with a microbiome narrative, and the challenge for practitioners becomes separating formulation-specific claims from the broader, well-supported science on skin barrier health and microbial diversity.

The context for practitioners

The skin microbiome category sits at the intersection of cosmeceuticals and clinical dermatology. Products in this space typically emphasize actives that claim to support or restore beneficial microbes rather than eliminate them — a reversal of the antibacterial framing that dominated skincare marketing for years.

For clinicians fielding patient questions triggered by consumer coverage of this kind, the practical takeaway is straightforward: patients are encountering microbiome language and will ask whether such products belong in their regimens. Dermatologists are best placed to contextualize those questions against what trial data, rather than marketing copy, actually supports.

As consumer interest in microbiome-first skincare continues to build, expect more clinician-backed brands to take their messaging directly to lifestyle media — and expect patients to bring that messaging into the clinic.